Homing Receptor Expression Is Deviated on CD56+ Blood Lymphocytes during Pregnancy in Type 1 Diabetic Women

Suzanne D. Burke1az, Alexandra V. C. Seaward1ab, Heather Ramshaw2, Graeme N. Smith3, Sophia Virani1, Barbara A. Croy1, Patricia D. A. Lima1ac

1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada, 2 Department of Obstetrics and Gynecology, Queen’s University, Kingston, Ontario, Canada

a Current address: Howard Hughes Medical Institute/Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
b Current address: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
c Current address: Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

limapda@gmail.com

Abstract

Type 1 Diabetes Mellitus (T1DM) is characterized by an augmented pro-inflammatory immune state. This contributes to the increased risk for gestational complications observed in T1DM mothers. In normal pregnancies, critical immunological changes occur, including the massive recruitment of lymphocytes, particularly CD56bright NK cells, into early decidua basalis and a 2nd trimester shift towards Type 2 immunity. Decidual CD56bright NK cells arise at least partly from circulating progenitors expressing adhesion molecules SELL and ITGA4 and the chemokine receptors CXCR3 and CXCR4. In vitro studies show that T1DM reduces interactions between blood CD56+ NK cells and decidual endothelial cells by reducing SELL and ITGA4-based interactions. To address the mechanisms by which specific lymphocyte subsets may be recruited from the circulation during pregnancy and whether these mechanisms are altered in T1DM, flow cytometry was used to examine eight peripheral blood lymphocyte subsets (Type 1 (IL18R1+) and Type 2 (IL1RL1+) CD56bright NK, CD56dim NK, NKT and T cells) from control and T1DM women. Blood was collected serially over pregnancy and postpartum, and lymphocytes were compared for expression of homing receptors SELL, ITGA4, CXCR3, and CXCR4. The decline of Type 1/Type 2 immune cells in normal pregnancy was driven by an increase in Type 2 cells that did not occur in T1DM. CD56bright NK cells from control women had the highest expression of all four receptors with greatest expression in 2nd trimester. At this time, these receptors were expressed at very low levels by CD56bright NK cells from T1DM patients. Type 1/Type 2 NKT cell ratios were not influenced by either pregnancy or T1DM. Our results suggest that T1DM alters immunological balances during pregnancy with its greatest impact on CD56bright NK cells. This implicates CD56bright NK cells in diabetic pregnancy complications.
Introduction

Type 1 Diabetes Mellitus (T1DM) significantly elevates risk for gestational complications such as premature birth, macrosomia, perinatal death and preeclampsia [1–4]. These risks occur despite appropriate glycemic control [3]. Enhanced pro-inflammatory responses characterize not only T1DM [5,6], but also several pregnancy disorders [7–9]. During normal pregnancy, circulating and tissue-specific decidual lymphocytes contribute to conceptus tolerance, vascular remodeling and placental development [10,11]. In early human decidua (a transient, uterine stromal cell-derived progesterone-dependent tissue), the most abundant lymphocytes are CD56bright Natural Killer cells (NK). Decidual CD56bright (d)NK cells secrete cytokines and angiokines, but display limited cytotoxic ability [10,11]. Origins of CD56bright dNK cells and other decidual lymphocytes are unclear. The possibility that they are derived from NK cell populations recruited from peripheral blood has been suggested [12–16]. However, research also supports recruitment at earlier lymphocyte stages or from other tissues as well as differentiation from resident self-renewing progenitors within the uterus [17]. Adoptive transfer studies in mice support all of these possibilities [18–20].

Previous research serially comparing cells from women at days 8 or 20 in a monitored menstrual cycle showed that CD56+ blood leukocytes collected at the LH surge have enhanced in vitro adhesion to endothelium of decidua basalis under shear forces [15]. Gains in in vitro adhesion to decidual endothelium are also reported in early pregnancy and have been linked with fertility [16]. In both studies, selectin L (SELL) and alpha 4 integrin (ITGA4)-based adhesion were identified as mechanisms promoting these changes in function [15, 16]. In contrast, blood CD56+ NK cells from pregnant T1DM and T2DM women are less adherent in vitro than blood CD56+ cells from gestational age-matched normal pregnant women to decidual endothelium, and more adherent to pancreatic endothelium [21]. SELL and ITGA4 alterations accounted for 75% of the functional change in diabetic CD56+ cell adhesion to decidual endothelium, suggesting that CD56+ NK cells in diabetic women had a diabetes-associated deviation in homing potential [21]. SELL and ITGA4 are strongly expressed by circulating CD56bright NK cells [22] and have been identified as key receptors that could direct CD56+ blood NK cell homing to the uterus [22,23]. Leukocyte homing to specialized environments also involves interactions between tissue-secreted chemokines and leukocyte-expressed chemokine receptors [24–26]. Decidua produces abundant CXCL10 and CXCL12 [27], chemokines that bind to CXCR3 and CXCR4 respectively. Blood CD56bright NK cells highly express CXCR3 and CXCR4 [24] that would enable lymphocyte-decidua interactions and promote lymphocyte retention within decidua. Stability in the expression of these receptors has not been assessed over pregnancy.

In the 1st trimester of normal human pregnancy, a Type 1 immune state (also referred to as Th1 or the physiological pro-inflammatory state that normally characterizes men and non-pregnant women) is present systemically. In late 2nd trimester, a shift towards Type 2 immunity (Th2 or anti-inflammatory state) occurs [28–30]. Here we compare the serial immune profiles (Type 1 or Type 2 immunity) and expression of selected homing receptors (ITGA4, SELL, CXCR3 and CXCR4) in blood lymphocyte subsets of normal pregnant women and T1DM women receiving regular prenatal medical care. Expression of IL18R1 or IL1RL1 was used to identify Type 1 and Type 2 lymphocytes, respectively, as previous described [30]. IL18R1 regulates IFNG [31], an important cytokine in early decidua [32]; as well as perforin expression in human decidual leukocytes, in vitro [33]. IL1RL1 through activation by IL33, a cytokine also expressed by early human decidua [34], is a crucial amplifier of innate rather than adaptive Type 2 immunity [34, 35].

We hypothesized that women with T1DM would have increased Type 1 lymphocyte bias throughout gestation and altered homing receptor expression on NK cell subsets. CD56bright
NK, CD56dim NK, NKT and CD3+T cell subsets were examined in a cross-sectional longitudinal study that followed 7 T1DM patients and 8 age-matched controls over pregnancy and postpartum. Our outcome data show that in well-monitored T1DM women, the shift to Type 2 lymphocyte-predominance in the 2nd trimester of pregnancy does not occur and the expression of homing receptors in blood lymphocytes is dampened compared with matched controls.

**Material and Methods**

**Subject recruitment**

Pregnant Caucasian women with T1DM (n = 7) and healthy, racially and age-matched controls (n = 8) were recruited at Kingston General Hospital (Kingston, ON, Canada). The T1DM women used insulin pumps and regularly visited the diabetic pregnancy clinic for supervised care. Exclusion criteria were multiple pregnancy, previous diagnosis or treatment of hypertension, polycystic ovarian syndrome, cancer and/or autoimmune disease other than T1DM. Patients provided a written consent and were free to withdraw at any time without any impact on their care. All patient samples were coded and blinded to investigators and no personal identifying information was recorded for study purposes. All protocols were pre-approved by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board.

Blood samples were serially collected at 11–13 weeks (1st trimester), 18–20 weeks (2nd trimester) and 33–35 weeks (3rd trimester) of gestation and after the 6th postpartum week from each subject as available. These blood samples represent all of those used in our previous report on functional leukocyte adhesion *in vitro* [21] that contained sufficient cells for this second independent leukocyte assay.

**Sample collection**

Blood was collected into acid citrate dextrose anti-coagulant by venipuncture (BDVacutainer, BD Bioscience; Mississauga, ON, Canada). Lymphocytes and plasma were immediately isolated by centrifugation (400 g; 30 min; 4°C) using Histopaque 1077 (Sigma Aldrich, St. Louis, MO, USA). Lymphocytes were collected, resuspended, washed thrice in phosphate buffered-saline (PBS), and then stained for flow cytometry.

**Flow cytometry**

5 x 10^5 cells/mL in 50μl of PBS containing 1% Bovine Serum Albumin (BSA) and 2% heat-inactivated human male serum were labeled using directly conjugated monoclonal antibodies and isotype controls. The antibodies and isotype controls, as well as the staining strategy are summarized in S1 Table and S2 Table respectively. After washing with 1% BSA in PBS and fixing with 2% paraformaldehyde, 1x10^5 events were collected using a FC500 flow cytometer (Beckman Coulter, Mississauga, ON, Canada). Post-acquisition compensation and analysis were performed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). Lymphocytes were analysed as CD56^{bright} NK, CD56^{dim} NK, NKT or T cells that expressed IL18R1 or IL1RL1 [30], followed by analysis of ITGA4, SELL, CXCR3 and CXCR4 expression.

**Multiplex cytokine/chemokines/growth factor microbead immunoassay**

A multiplex biometric immunoassay, containing fluorescent microspheres conjugated with a monoclonal antibody specific for a target protein, was used for cytokine measurement according to the manufacturer’s instructions (Bio-Plex Human Cytokine Assay # M50–0KCA0Y; Bio-Rad Inc., Hercules, CA, USA). For this assay, six patients from the control group had plasma available. All seven plasma samples from T1DM patients were tested in this assay.
Statistical analyses

Demographic data for subjects used in the flow cytometric analyses are presented as means ± SEM, unless otherwise specified, and compared by t-test. Lymphocyte subset data are presented as a percentage of total lymphocytes or percent positive of specified subset. Some data were log transformed to normalize their distribution and permit statistical analyses. Flow cytometry data were subjected to Grubb’s test to exclude outliers, followed by analysis between groups using two-way ANOVA with Bonferroni’s post-test. This was followed by one-way ANOVA with Bonferroni’s or Dunn’s post-tests, as applicable. To determine the impact of two T1DM patients who were diagnosed with preeclampsia after donation of their 3rd trimester sample, analyses were repeated (as described above) excluding these patients from the T1DM group. The data from multiplex biometric immunoassay were tested for the normality using Shapiro-Wilk test, and compared using the Mann Whitney-U test.

Data were analyzed using Prism 5 Statistical Software package (GraphPad, San Diego, CA, USA). P values of <0.05 were considered statistically significant.

Results and Discussion

Patient demographics

Maternal demographics and clinical data are presented in Table 1. Two T1DM patients developed preeclampsia after donation of their 3rd trimester sample. Both patients donated postpartum samples. The systolic blood pressure of T1DM patients was significantly higher than controls and the T1DM patients delivered preterm. Despite receiving regular pre-natal care at

| Table 1. Maternal and delivery demographics of control and T1DM patients. |
|-----------------|-----------------|-------|
| Control (n = 8) | T1DM (n = 7)    | P     |
| Age (years)     | 28.13 ± 1.85   | 25.71 ± 1.77 | 0.37 |
| Obstetrical History |               |       |     |
| Gravida         | 1.50 ± 0.19    | 2.14 ± 0.86 | 0.45 |
| Term Deliveries | 0.50 ± 0.19    | 0.00 ± 0.00 | 0.03 |
| Preterm Deliveries | 0.13 ± 0.13 | 0.43 ± 0.30 | 0.34 |
| Pregnancy Loss  | 0.00 ± 0.00    | 0.71 ± 0.57 | 0.20 |
| Living Children | 0.38 ± 0.18    | 0.14 ± 0.14 | 0.35 |
| Delivery Information |           |       |     |
| GAD (weeks)     | 39.80 ± 0.81   | 35.65 ± 1.48 | 0.05 |
| BW (g)          | 3749.11 ± 230.82 | 3407.00 ± 267.77 | 0.36 |
| SVD             | 80%            | 57%   | 0.32 |
| C-section       | 20%            | 43%   | 0.32 |
| Clinical Data   |                |       |     |
| Systolic Blood Pressure (mmHg) | 115.13±2.06 | 132.26±2.97 | 0.02 |
| Diastolic Blood Pressure (mmHg) | 73.16±1.47 | 72.74±2.32 | 0.87 |
| Blood Glucose (mmol/L) | NAD     | 8.73 (± 1.16) | -     |
| HbA1C (% of Hb) | NAD           | 7.54 (± 0.81) | -     |
| Urine protein/24 hour (mg/dL) | 3.08±2.30 | 21.47±17.49 | 0.39 |

Data are presented as mean ± SEM or percentage. GAD, gestation age at delivery. BW, birth weight of newborn. SVD, spontaneous vaginal delivery. C-section, Caesarean section, NAD, no abnormality detected. Normal ranges for blood glucose (3.3–5.6 mmol/L) and HbA1C (3.6–5.0% of Hb). Trace values for urine protein/24 hour are 5–20 mg/dL.

doi:10.1371/journal.pone.0119526.t001
a high-risk, tertiary care hospital-based pregnancy clinic, glycemic control fluctuated. Using White’s classification of Diabetic Pregnancy, four T1DM were qualified as Class C and three were Class D (including both preeclamptic patients).

Circulating lymphocytes across control and T1DM pregnancies

Lymphocytes were gated on forward scatter and side scatter properties. Based on CD3 and CD56 profiles, four lymphocyte subsets were analyzed: CD3 CD56\textsuperscript{bright}, CD3 CD56\textsuperscript{dim}, CD3\textsuperscript{*}CD56\textsuperscript{*}, NK cells, CD3\textsuperscript{*}CD56\textsuperscript{*}, NKT cells and CD3\textsuperscript{*}CD56\textsuperscript{*}, T cells (Fig. 1A). The proportions of NK CD56\textsuperscript{bright}, NK CD56\textsuperscript{dim}, NKT and T cells were invariant across pregnancy and postpartum and were not significantly different between control and T1DM patients (Fig. 1B).
Type 1 vs Type 2 lymphocyte ratios across control and T1DM pregnancies

i) Global lymphocyte analyses. IL18R1 and IL1RL1 were used as surface molecules to identify Type 1 and Type 2 biased lymphocytes, respectively [30,31] and the ratio of Type 1/Type 2 lymphocytes was calculated. The Type 1/Type 2 lymphocyte ratios for control patients were highest in 1st trimester and declined in later trimesters and postpartum (P = 0.0065; Fig. 2). The decline was driven by an increase in Type 2 lymphocytes. This shift of immunity from Type 1 (1st trimester) towards Type 2 in later gestation is similar to data reported by others for normal human pregnancies [29,30]. In contrast, for T1DM patients, Type 1/Type 2 total lymphocyte ratios were invariant across pregnancy and postpartum (Fig. 2). Thus, no Type 2 immune shift occurred during pregnancy in T1DM patients.

ii) Lymphocyte subset analyses. The proportions of lymphocyte subsets (CD56^bright NK, CD56^dim NK, NKT and T cells) expressing IL18R1 (Type 1 cells) did not differ significantly between control and T1DM patients over pregnancy and postpartum (Fig. 3A; S3 Table). However, Type 2 (IL1RL1^+) CD56^bright NK, CD56^dim NK and T cells increased significantly in control patients in 2nd trimester (Fig. 3B; S3 Table; P<0.05), while lymphocytes from T1DM patients expressing IL1RL1 were invariant over pregnancy and postpartum (Fig. 3B; S3 Table). NKT cells were invariant across pregnancy and postpartum in control and T1DM patients. These data suggest that specific subsets of CD56^bright NK, CD56^dim NK and T cells participate in the shift of immunity from Type 1 towards Type 2 in 2nd trimester of normal pregnancy. They further indicate that by 18–20 weeks gestation in T1DM patients, a physiological change fails to occur amongst CD56^bright NK, CD56^dim NK and T cells.

Type 1/Type 2 ratios were also calculated for each lymphocyte subset as described below (Fig. 4A-D).
CD56<sup>bright</sup> NK cells: In control patients, the Type 1/Type 2 ratio of CD56<sup>bright</sup> NK cell was lower in 2<sup>nd</sup> compared to 1<sup>st</sup> trimester, demonstrating the expected shift towards a Type 2 profile (P<0.05). At 3<sup>rd</sup> trimester, the ratio was significantly higher than in 2<sup>nd</sup> trimester (P<0.05). In T1DM patients, the Type 1/Type 2 ratio of CD56<sup>bright</sup> NK cells was significantly higher in 1<sup>st</sup> trimester than postpartum (P<0.05), but no differences were found comparing 1<sup>st</sup>, 2<sup>nd</sup> and
3rd trimesters. No significant differences in the Type 1/Type 2 ratio of CD56\textsuperscript{bright} NK cells were found between control and T1DM patients in any pregnancy or postpartum period (Fig. 4A).

CD56\textsuperscript{dim} NK cells: In control patients, the Type 1/Type 2 ratio of CD56\textsuperscript{dim} NK cells declined from 1st trimester to the postpartum period (P < 0.05; Fig. 4B). In T1DM patients, no alterations occurred. No significant differences were found between control and T1DM patients for any pregnancy or postpartum period (Fig. 4B).

CD\textsuperscript{3}CD56\textsuperscript{+} NKT cells: Type 1/Type 2 ratios did not differ across pregnancy and postpartum in either patient group or between patient groups (Fig. 4C). Thus, the Type 1/Type 2 NKT cell ratio in blood is not influenced by either pregnancy or T1DM.

CD\textsuperscript{3}CD56\textsuperscript{-} T cells: In control patients, the Type 1/Type 2 ratio expressed by T cells was lower in 2nd compared to 1st trimester (P < 0.05), consistent with a shift towards a Type 2 immune profile. A similar reduction was not observed in T1DM patients (Fig. 4D). No differences were observed when Type 1/Type 2 T cell ratios were compared between control and T1DM patients.

Exclusion of data from the two T1DM patients who subsequently became preeclamptic did not alter outcomes from these analyses. That is, Type 1/Type 2 ratios were stable for all lymphocyte subsets of the T1DM women. This suggests that T1DM, whether or not it is

![Fig 4. Type 1/Type 2 ratio (IL18R1\textsuperscript{+}/IL1RL1\textsuperscript{+}) of specific lymphocyte subsets. Type 1/Type 2 ratio of CD56\textsuperscript{bright} NK cells (A), CD56\textsuperscript{dim} NK cells (B), NKT cells (C) and T cells (D). The data are expressed as percentage following lognormal transformation (A) and percentage (B-D) of cells expressing IL18R1/IL1RL1. (A) Type 1/Type 2 ratio of CD56\textsuperscript{bright} NK cells was significantly lower in 2nd trimester compared with 1st and 3rd trimesters in control pregnancies (\*P < 0.05), but not in T1DM patients. (B) CD56\textsuperscript{dim} NK cells had significantly higher Type 1/Type 2 ratios in 1st trimester control than postpartum samples (\*P < 0.05). CD56\textsuperscript{dim} NK cells Type 1/Type 2 ratio from T1DM patients did not significantly differ across pregnancy and postpartum. (C) Type 1/Type 2 ratios of NKT cells did not differ significantly across pregnancy and postpartum in control and T1DM patients, or between control and T1DM patients. (D) Type 1/Type 2 ratio for T cells was higher in 1st than 2nd trimesters in control pregnancies (\*P < 0.05), but not in T1DM patients.](doi:10.1371/journal.pone.0119526.g004)
accompanied by preeclampsia, interferes with the normal gestational shift from Type 1 to Type 2 immunity in CD56\textsuperscript{bright} NK cells, CD56\textsuperscript{dim} NK cells and in T cells. This finding is also consistent with previous studies in preeclamptic, non-diabetic patients who demonstrated failure to convert from Type 1 to Type 2 cytokine bias [30]. This could represent a common immune pathway, or potential mechanism promoting diabetogenic risk for preeclampsia, but requires further study.

Expression of adhesion and chemokine receptors across control and T1DM pregnancies and postpartum

The percentages of each lymphocyte subset expressing ITGA4 and SELL, and CXCR3 and CXCR4 were examined during pregnancy and postpartum. These data are summarized in S4 Table and S5 Table. CD56\textsuperscript{bright} NK cells were the subset with highest expression of each of the receptors and with the largest changes in homing receptor expression across pregnancy and postpartum.

Type 2 CD56\textsuperscript{bright} NK cells were the lymphocytes showing the greatest variation in homing receptor expression in control pregnancies, suggesting that this subset has the greatest ability to home to tissues from blood. Type 2 CD56\textsuperscript{bright} NK cells from control women expressed ITGA4 at higher levels in 2\textsuperscript{nd} trimester than in 1\textsuperscript{st} or 3\textsuperscript{rd} trimesters (Fig. 5A). Type 2 CD56\textsuperscript{bright} NK cells from control patients also had greater expression of SELL, CXCR3 and CXCR4 during

![Fig 5. Homing receptor expression by Type 2 CD56\textsuperscript{bright} NK cells.](image)

In (A) the percentage of Type 2 CD56\textsuperscript{bright} NK cells expressing ITGA4 in control patients was significantly increased in the 2\textsuperscript{nd} trimester versus 1\textsuperscript{st} and 3\textsuperscript{rd} trimesters (\(\ast P < 0.05\)). No significant differences were detected in T1DM patients. In (B) Log of and (C-D) percentage of Type 2 CD56\textsuperscript{bright} NK cells expressing SELL (B), CXCR3 (C) and CXCR4 (D) are shown. A significant increase in Type 2 CD56\textsuperscript{bright} NK cells expressing SELL (B), CXCR3 (C) and CXCR4 (D) was detected in 2\textsuperscript{nd} compared to 1\textsuperscript{st} trimester (\(\ast P < 0.05; \ast \ast P < 0.01\)). Type 2 CD56\textsuperscript{bright} NK cells expressing CXCR3 were also significantly higher in 2\textsuperscript{nd} trimester than postpartum (\(\ast P < 0.05\)). Control patients had more Type 2 CD56\textsuperscript{bright} NK cells expressing SELL (B), CXCR3 (C) and CXCR4 (D) than T1DM patients in 2\textsuperscript{nd} trimester (\(# P < 0.05\)).

doi:10.1371/journal.pone.0119526.g005
2nd trimester compared to 1st trimester (Fig. 5B-D). In T1DM patients, few Type 2 CD56<sup>bright</sup> NK cells expressed SELL, CXCR3 or CXCR4 at 2nd trimester (Fig. 5B-D).

ITGA4 and SELL expression by circulating CD56<sup>bright</sup> NK cells is widely known to be important for NK cell adhesion, interaction with endothelium and extravasation [15, 36, 37]. Our data suggest that extravasation of Type 2 CD56<sup>bright</sup> NK cells is preferentially increased only during the 2nd trimester of normal pregnancy while the potential for extravasation of Type 1 CD56<sup>bright</sup> NK cells is high in both 1st and 2nd trimesters. In normal pregnancy, reduced expression of ITGA4 and SELL occurs in Type 1 and Type 2 blood NK cells during 3rd trimester, an interval during which fewer CD56<sup>bright</sup> NK cells are present in decidua [38]. The homing of CD56<sup>bright</sup> NK cells into decidual tissue also involves CXCR3 and CXCR4 [12, 14, 27, 39].

T1DM-associated reductions in SELL and ITGA4 expression by Type 2 CD56<sup>bright</sup> NK cells during 2nd trimester may explain the observation that CD56<sup>+</sup> blood lymphocytes from these same 2nd trimester T1DM pregnancies had reduced in vitro binding to mouse decidual endothelium [21].

Changes in homing receptor expression also occurred in Type 2 CD56<sup>dim</sup> NK cells. In control patients, CD56<sup>dim</sup> NK cells expressing SELL and CXCR3 were significantly higher in 3rd than in 1st or 2nd trimesters (Fig. 6A, B), while in T1DM patients no changes were detected. Type 2 CD56<sup>dim</sup> NK cells expressing CXCR3 were significant lower in T1DM than control patients at 3rd trimester (Fig. 6B).

Two subsets of Type 1 lymphocytes varied in homing receptor expression: CD56<sup>bright</sup> NK cells and NKT cells. Type 1 CD56<sup>bright</sup> NK cells expressing ITGA4 were significantly higher in 1<sup>st</sup> (92.4±5.3) and 2<sup>nd</sup> (94.8±3.7) trimester than in 3<sup>rd</sup> (78.4±8.7) trimester from control pregnancies (P<0.05; Fig. 7A). Conversely, no alterations were observed in CD56<sup>bright</sup> NK cell expression of any homing receptor across pregnancy and postpartum in T1DM patients. Comparisons between control and T1DM patients demonstrated that Type 1 CD56<sup>bright</sup> NK cells expressing ITGA4 were more frequent in T1DM than control patients in 3<sup>rd</sup> trimester (78.4±8.7 vs. 91.0±5.5, P<0.05; Fig. 7A). This finding may suggest that in T1DM, the need for high levels of uNK cell functions persists at the maternal fetal interface longer (into 3<sup>rd</sup> trimester) than in normal pregnancies and that a compensatory response has occurred to sustain CD56<sup>bright</sup> NK cell extravasation. The timing of this difference also coincides with onset rapid fetal growth and of clinical recognition of preeclampsia and may reflect a lymphocyte phenotype induced by tissue-specific endothelial cell stress [30, 40–42].

---

**Fig 6. Homing receptor expression by Type 2 CD56<sup>dim</sup> NK cells.** Percentage of Type 2 CD56<sup>dim</sup> NK cells expressing SELL (A) and CXCR3 (B). (A) Type 2 CD56<sup>dim</sup> NK cells expressing SELL from control patients in 3rd trimester were higher than in 1st trimester (*P<0.05). No differences in Type 2 CD56<sup>dim</sup> NK cells were detected over pregnancy in T1DM patients. (B) Control 3<sup>rd</sup> trimester patients had a higher percentage of Type 2 CD56<sup>dim</sup> NK cells expressing CXCR3 than in 1<sup>st</sup> (**P<0.01) or 2<sup>nd</sup> trimesters (**P<0.05). The Type 2 CD56<sup>dim</sup> NK cells from T1DM patients did not differ across pregnancy. Type 2 CD56<sup>dim</sup> NK cells expressing CXCR3 in the 3<sup>rd</sup> trimester were numerous in control than T1DM patients (#P<0.05).

doi:10.1371/journal.pone.0119526.g006
The analysis of homing receptors expressed by Type 1 NKT cells showed that T1DM patients, but not control patients, vary during pregnancy. In T1DM patients, Type 1 NKT cells expressing ITGA4 were significantly reduced at postpartum (23.2%±11.4) compared to 3rd trimester (63.5%±13.0; P<0.05, Fig. 7B). Comparisons between control and T1DM patients demonstrated that at 1st trimester (69.1%±15.2 vs. 32.6%±19.9) and postpartum (56.5%±19.3 vs. 23.2%±11.4), fewer Type 1 NKT cells expressing ITGA4 were measured in T1DM than control patients (control vs. T1DM respectively, P<0.05; Fig. 7B). Exclusion of the two preeclamptic
patients from these analyses annulled the statistical differences. ITGA4 involvement in NKT cell homing potential for decidua is compatible with its higher expression in peripheral NKT cells of fertile versus infertile women [43]. Since no control patients developed preeclampsia, the implications of the altered expression of ITGA4 on Type 1 NKT cells in preeclampsia remains unclear.

Adoptive transfer experiments in mice [18] and analyses of human decidua [44] supports the conclusion that decidual lymphocytes arise from cells that home from the circulation. Further, in vitro differentiation of CD56⁺ blood NK cells into decidua-like CD16 CD56⁺bright \[45\] is reported. However, endometrial hematopoietic progenitor cells (CD34⁺CD45⁺) are also described in first trimester \[17\]. Thus, at least in early decidua, hematopoietic progenitor cells may contribute significantly to the gains in decidual NK cells, as predicted by their capacity for in vitro differentiation \[17\]. Few published reports have addressed the presence or life span of decidual hematopoietic progenitor cells that can differentiate into decidual CD56⁺bright NK cells beyond 1st trimester. Such studies are limited largely by ethical constraints. Bulmer and Lash \[38\] found high numbers of CD56⁺ uNK cells in placental bed biopsies until week 20 of pregnancy (2nd trimester). The life span of uNK cells can only be surmised from estimates of peripheral NK cells. The half-life of human NK cells has been estimated at about 12 days \[46\]. This is similar to the estimated half-life of peripheral mouse NK cells \[47,48\]. The main differences between our normal and T1DM study participants were found in 2nd trimester, a time that may represent a secondary wave of leukocyte recruitment to the decidua from the circulation. The enrichment of different lymphocyte subsets (functionally and phenotypically) in decidua as pregnancy progresses is widely accepted. The data presented here add to understanding that over the course of normal pregnancy, the potential for tissue recruitment of circulating NK and T cells is dynamic and differs between lymphocyte subsets, with CD56⁺bright NK cells showing the highest and most dynamic expression of key receptors. We also show that a disease process, T1DM, depresses these receptor changes in a manner that might reduce important lymphocyte-based functions at the maternal-fetal interface.

Cytokines, chemokines and growth factors across control and T1DM pregnancies and postpartum

11 analytes (IL1B, IL2, IL5, IL6, IL8, IL10, IL13, IL15, CSF2, VEGF and TNF) were undetectable in all samples tested. 10 analytes (IL9, IL12, IL17, FGF, IFNG, CCL3, CCL11, ILR1A, IL4 and PDGF) were sporadically detected in control and T1DM patients; cytokines tended to be less frequently detected in T1DM patients (Fig. 8). Due to the variable nature of the data, statistical comparison is not straightforward. Cytokine analysis was done on unstimulated samples, which may explain low/undetectable values. With this consideration, in T1DM patients, IFNG was less frequently detected in the 1st, 2nd and 3rd trimesters compared to control patients. Although non-conclusive, six analytes (IL7, CSF3, CXCL10, CCL2, CCL4 and CCL5) were detected in all samples and statistically analyzed. Only plasma IL7 and CSF3 were significantly lower in T1DM than control patients at 2nd trimester (Table 2). IL7 supports the differentiation and functions of multiple lymphoid and myeloid lineages [49,50]; including CD56⁺bright NK cells [51], but knowledge concerning the role of IL7 during pregnancy is limited. However, a potential role for IL7 in induction of expression of CXCR3, CXCR4 and other integrins is reported in T lymphocytes [52–54]. This may be linked with the increased number of homing receptors expressed by blood CD56⁺bright NK cells in control, but not in T1DM patients. Larger number of patients and in vitro studies would be required to address this possible mechanism. CSF3 was also up regulated in control patients at 2nd trimester, but not in T1DM (Table 2). Although more frequently studied during labor [55], CSF3 is reported to promote Type 2
cytokine secretion, activate T regulatory cells [56], and stimulate endometrial vascular remodeling ex-vivo [57]. These functions could aid in coordination of the shift to Type 2 immune state observed in control patients in 2nd trimester, which is not seen in T1DM patients. Confirmatory and functional studies are necessary to establish the importance and mechanistic roles for CSF3 deficiency in T1DM pregnancies.

Table 2. Cytokine concentrations in control and T1DM plasma across pregnancy and postpartum.

| Cytokine | 1st trimester | 2nd trimester | 3rd trimester | Postpartum |
|----------|---------------|---------------|---------------|------------|
|          | Control       | T1DM          | Control       | T1DM       | Control       | T1DM       | Control       | T1DM       |
| IL7      | 5.1 (3.1, 1.7) | 6.05 (4.6, 7.3) | 2.3 (2.1, 5.0) | 0.03       | 3.9 (5.2, 0.7) | 2.2 (2.0, 0.7) | 0.10       | 6.1 (15.7, 5.4) | 7.5 (0.42) |
| CSF3     | 67.2 (40.7, 17.2) | 85.8 (81.1, 100.7) | 32.3 (21.5, 68.4) | 0.04       | 60.1 (63.3, 17.2) | 45.2 (41.5, 152.9) | 104.6 (131.8) | 0.69       |
| CXCL10   | 367.0 (147.2, 381.4) | 421.8 (350.5, 381.4) | 230.5 (210.1, 339.3) | 0.06       | 362.5 (122.8, 318.5) | 426.2 (362.5, 406.5) | 0.69       |
| CCL2     | 21.2 (10.7, 26.3) | 7.0 (25.9, 17.4) | 9.2 (24.3, 14.3) | 0.06       | 31.9 (10.9, 29.5) | 10.9 (31.9, 18.5) | 11.0 (6.9)   |
| CCL4     | 33.9 (19.2, 38.2) | 24.3 (34.0, 22.2) | 15.8 (38.0, 20.1) | 0.69       | 40.2 (23.2, 36.9) | 15.5 (40.2, 23.2) | 1.0 (1.0)    |
| CCL5     | 384.8 (509.1, 89.5) | 238.1 (324.2, 342.7) | 172.4 (346.5, 346.5) | 0.08       | 306.6 (363.3, 93.3) | 295.2 (438.2, 833.2) | 243.1 (916.4) | 0.91       |

Mann-Whitney-U test (non-normal distribution; P < 0.05 found only for IFNG in the 1st trimester. T1DM calculations shown include women who became preeclamptic in 3rd trimester.)

doi:10.1371/journal.pone.0119526.t002
Conclusions

This study demonstrates that the impact of normal pregnancy on circulating NK and T cell subsets is not uniform. In control women, NK and T cell subsets convert from Type 1 to Type 2 immune dominance in 2nd trimester. Amongst these subsets, CD56<sup>bright</sup> NK cells from normal pregnant women express the highest levels of receptors for extravasation and chemokine-directed movement into tissues and this expression is temporally dynamic. In T1DM gestations, no conversion to Type 2 immune profile was observed amongst the eight NK and T cell subsets examined. Thus, a pro-inflammatory systemic environment is maintained throughout T1DM pregnancies, although plasma IFNG, IL7 and CSF3 were lower in TIDM than control patients. Further, in T1DM women, reduced expression of key receptors for endothelial cell interactions and decidual homing occurs during 2nd trimester in circulating Type 2 CD56<sup>bright</sup> NK cells. These alterations may reduce normal lymphocyte homing into decidua. A sustained Type 1 pro-inflammatory milieu in the periphery is a known deviation from healthy gestation. Understanding the mechanisms causing the heightened Type 1 status of pregnant T1DM women would likely reveal potential therapeutic targets. The goal would be to promote Type 2 CD56<sup>bright</sup> NK cell homing to decidua where pro-angiogenic, anti-inflammatory functions are thought to promote physiological gestations, free from complications [58].

Supporting Information

S1 Table. Panel of antibodies used for flow cytometric analyses of lymphocyte subsets. All antibodies were monoclonal mouse anti-human.

S2 Table. Flow cytometry-staining strategy. A total of 18 tubes were read for each patient. Compensation was completed post-acquisition individually for each multiple color sample.

S3 Table. Type 1 lymphocyte (IL18R1+) and Type 2 lymphocyte (IL1RL1+) percentage in control and T1DM patients across pregnancy and postpartum. Mean±SD of percentage of Type 1 and Type 2 lymphocyte subsets. * Significance between periods (1st, 2nd, 3rd trimester and postpartum within each patient group); #: significance between patients (control and T1DM within a specific test interval). P <0.05.

S4 Table. Adhesion molecule and chemokine receptor expression by Type 1 blood lymphocytes across pregnancy and postpartum. Data are percentage mean ± SEM of Type 1 cells expressing a specific adhesion molecule or chemokine receptor. * P<0.05 and ** P<0.01. Significance between periods (1st, 2nd, 3rd trimester and postpartum within each patient group) is not shown in this table. T1DM calculations shown include women who became pre-eclamptic in 3rd trimester.

S5 Table. Adhesion molecule and chemokine receptor expression by Type 2 blood lymphocytes across pregnancy and postpartum. Data are percentage mean ± SEM of Type 2 cells expressing a specific adhesion molecule or chemokine receptor. * P<0.05 and ** P<0.01. Significance between periods (1st, 2nd, 3rd trimester and postpartum within each patient group) is not shown in this table. T1DM calculations shown include women who became pre-eclamptic in 3rd trimester.
Acknowledgments
We thank Richard DiLena for technical support.

Author Contributions
Conceived and designed the experiments: SDB BAC GNS. Performed the experiments: SDB AVCS HR. Analyzed the data: SDB AVCS HR BAC SV PDAL. Contributed reagents/materials/analysis tools: GNS BAC. Wrote the paper: SDB AVCS BAC PDAL.

References
1. Yu Y, Jenkins AJ, Nankervis AJ, Hanssen KF, Scholz H, Lorentzen B, et al. Anti-angiogenic factors and preeclampsia in type 1 diabetic women. Diabetologia. 2009; 52(1): 160–168. doi: 10.1007/s00125-008-1182-x PMID: 18985316
2. Holmes VA, Young IS, Patterson CC, Maresh MJA, Pearson DWM, Walker JD, et al. Preeclampsia Intervention Trial (DAPIT) Study Group The Role of Angiogenic and Antiangiogenic Factors in the Second Trimester in the Prediction of Preeclampsia in Pregnant Women With Type 1 Diabetes. Diabetes Care. 2013; 36(11): 3662–3677. doi: 10.2337/dc13-0944 PMID: 23920083
3. Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: Nationwide prospective study in the Netherlands. BMJ. 2004; 328: 915. PMID: 15066886
4. Taylor R, Davison JM. Type 1 diabetes and pregnancy. BMJ. 2007; 334: 742–745. PMID: 17413175
5. Veihik K, Ajami NJ, Hadley D, Petrosino JF, Burkhardt BR. The changing landscape of type 1 diabetes: recent developments and future frontiers. Curr Diab Rep. 2013; 13(5): 642–650. doi: 10.1007/s11892-013-0406-8 PMID: 23912764
6. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010; 10(7): 501–513. doi: 10.1038/nri2787 PMID: 20577267
7. Wallace AE, Host AJ, Whitley GS, Cartwright JE. Decidual natural killer cell interactions with trophoblasts are impaired in pregnancies at increased risk of preeclampsia. Am J Pathol. 2013; 183(6): 1853–1861. doi: 10.1016/j.ajpath.2013.08.023 PMID: 24103555
8. Chazara O, Xiong S, Moffett A. Maternal KIR and fetal HLA-C: a fine balance. J Leukoc Biol. 2011; 90(4): 703–716. doi: 10.1189/jlb.0511227 PMID: 21873457
9. Williams PJ, Bulmer JN, Searle RF, Innes BA, Robson SC. Altered decidual leucocyte populations in the placental bed in pre-eclampsia and foetal growth restriction: a comparison with late normal pregnancy. Reproduction. 2008; 138(1): 177–184. doi: 10.1530/REP-08-0007 PMID: 19357190
10. Hanna J, Goldman-Woh D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006; 12: 1065–1074. PMID: 16892062
11. Lash GE, Naruse K, Robson A, Innes BA, Searle RF, Robson SC et al. Interaction between uterine natural killer cells and extravillous trophoblast cells: effect on cytokine and angiogenic growth factor production. Hum Reprod. 2011; 26(9): 2289–2296. doi: 10.1093/humrep/der198 PMID: 21685139
12. Carlino C, Stabile H, Morrone S, Bulla R, Soriani A, Agostinis C, et al. Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. Blood. 2008; 111(6): 3108–3115. doi: 10.1182/blood-2007-09-105965 PMID: 18187694
13. Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol. 2004; 173(11): 6760–6766. PMID: 15557169
14. Wu X, Jin LP, Yuan MM, Zhu Y, Wang MY, Li DJ. Human first-trimester trophoblast cells recruit CD56brightCD16- NK cells into decidua by way of expressing and secreting of CXCL12/stromal cell-derived factor 1. J Immunol. 2005; 175: 61–68. PMID: 15972632
15. van den Heuvel MJ, Xie X, Tayade C, Peralta C, Fang Y, Leonard S, et al. A review of trafficking and activation of uterine natural killer cells. Am J Reprod Immunol. 2005; 54(6): 322–331. PMID: 16305657
16. van den Heuvel MJ, Hatta K, Peralta CG, Han VK, Clark DA. CD56+ cells are recruited to the uterus in two waves: at ovulation and during the first 2 weeks after missed menses. Am J Reprod Immunol. 2008; 59(2): 90–98. PMID: 18076635
17. Vaccarino V, Moretta L, Moretta A, Mingari MC. Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol. 2011; 32(11): 517–523. doi: 10.1016/j.it.2011.06.013 PMID: 21894052
Outcomes of T1DM in Circulating Lymphocytes during Pregnancy

18. Chantakru S, Miller C, Roach LE, Kuziel WA, Maeda N, Wang WC, et al. Contributions from self-renewal and trafficking to the uterine NK cell population of early pregnancy. J Immunol. 2002; 168(1): 22–28. PMID: 11751942

19. Zhang JH, Yamada AT, Croy BA. DBA-lectin reactivity defines natural killer cells that have homed to mouse decidua. Placenta. 2009; 11: 968–973. doi: 10.1016/j.placenta.2009.08.011 PMID: 19765824

20. Chen Z, Zhang J, Hatta K, Lima PD, Yadi H, Colucci F, et al. DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression. Biol Reprod. 2012; 87(4): 81. doi: 10.1095/biolreprod.112.102293 PMID: 22875907

21. Seaward AVC, Burke SD, Ramshaw H, Smith GN, Croy BA. Circulating CD56+ cells of diabetic women show deviated homing potential for specific tissues during and following pregnancy. Hum Reprod. 2011; 26(7): 1675–1684. doi: 10.1093/humrep/der114 PMID: 21489978

22. Peralta CG, Han VK, Horrocks J, Croy BA, van den Heuvel MJ. CD56bright cells increase expression of (alpha)4 integrin at ovulation in fertile cycles. J Leukoc Biol. 2008; 84(4): 1065–1074. doi: 10.1189/jlb.0308164 PMID: 18628406

23. Chantakru S, Wang WC, van den Heuvel M, Bashar S, Simpson A, Chen Q, et al. Coordinate regulation of lymphocyte-endothelial interactions by pregnancy-associated hormones. J Immunol. 2003; 171(8): 4011–4019. PMID: 14530321

24. Campbell JJ, Qiong S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2011; 166: 6477–6482.

25. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994; 76: 301–314. PMID: 7507411

26. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol. 2000; 12: 336–341. PMID: 10781407

27. Red-Horse K, Drake PM, Gunn MD, Fisher SJ. Chemokine ligand and receptor expression in the pregnant uterus: reciprocal patterns in complementary cell subsets suggest functional roles. Am J Pathol. 2001; 159: 2199–2213. PMID: 11733370

28. Vince GS, Johnson PM. Is there a Th2 bias in human pregnancy? J Reprod Immunol. 1996; 32: 101–104. PMID: 9023814

29. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol. 1999; 117: 550–555. PMID: 10469061

30. Borzyschowski AM, Croy BA, Chan WL, Redman CWG, Sargent IL. Changes in systemic type 1 and type 2 immunity in normal pregnancy and preeclampsia may be mediated by natural killer cells. Eur J Immunol. 2005; 35(10): 3054–3063. PMID: 16134082

31. Chan WL, Pejnovic N, Lee CA, Al-Ali NA. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol. 2001; 167(3): 1238–1244. PMID: 11466339

32. Murphy SP, Tayade C, Ashkar AA, Hatta K, Zhang J, Croy BA. Interferon Gamma in successful pregnancies. Biol Reprod. 2009; 80: 848–859. doi: 10.1095/biolreprod.108.073353 PMID: 19164174

33. Tok madzic VS, Tsuji Y, Bogovic T, Laskaridjka K, Strobo N, et al. IL-18 is present at the maternal–fetal interface and enhances cytotoxic activity of decidual lymphocytes. Am J Reprod Immunol. 2002; 48: 191–200. PMID: 12516629

34. Salker MS, Nautiyal J, Steel JH, Webster Z, Sucurovic S, Nicou M, et al. Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss. PlosOne. 2012; 12: e52252. doi: 10.1371/journal.pone.0052252 PMID: 23300625

35. Oboki K, Nakae S, Matsumoto K, Saito H. IL-33 and airway inflammation. AAIR. 2011; 3(2): 81–88. doi: 10.4168/aair.2011.3.2.81 PMID: 21461246

36. Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol. 1998; 161: 400–408. PMID: 9647249

37. Gismondi A, Morrone S, Humphries MJ, Piccoli M, Frati L, Santoni A. Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin. J Immunol. 1991; 146(1): 384–392. PMID: 1701798

38. Bulmer JN, Lash GE. Human uterine natural killer cells: a reappraisal. Mol Immunol. 2005; 42(4): 511–521. PMID: 15607807

39. Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16-human natural killer cells. Blood. 2003; 102(5): 1569–1577. PMID: 12730110
40. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006; 11(5): 309–316. PMID: 16828580
41. Rao RM, Yang L, Garcia-Cardena G, Luscinaskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res. 2007; 101(3): 234–247. PMID: 17673684
42. Tognarelli S, Gayet J, Lambert M, Dupuy S, Karras A, Cohen P, et al. Tissue-specific microvascular endothelial cells show distinct capacity to activate NK cells: implications for the pathophysiology of granulomatosis with polyangiitis. J Immunol. 2014; 192(7): 3399–3408. doi: 10.4049/jimmunol.1301508 PMID: 24600034
43. van den Heuvel M, Peral CG, Hatta K, Han VK, Clark DA. Decline in number of elevated blood CD3+CD56+ NKT in response to intravenous immunoglobulin treatment correlates with successful pregnancy. Am J Reprod Immunol. 2007; 58: 447–459. PMID: 17922698
44. Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol. 2010; 185(7): 3913–3918. doi: 10.4049/jimmunol.1001637 PMID: 20802153
45. Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, et al. TGFβ promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci. 2007; 104(9): 3378–3383. PMID: 17360654
46. Zhang Y, Wallace DL, Lara CM, Halla G, Asquith B, Worth A, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007; 121: 258–265. PMID: 17346281
47. Wang JW, Howson JM, Ghansah T, Desponts C, Ninos JM, May SL, et al. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science. 2002; 295: 2094–2097. PMID: 11896280
48. Ranson T, Vosshenrich CAJ, Corcuff E, Richard O, Muller W, Di Santo JP. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood. 2013; 101(12): 4887–4893.
49. Cellab M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1B reveals intrinsic functional plasticity. PNAS. 2010; 107 (24): 10961–10966. doi: 10.1073/pnas.1005641107 PMID: 20534450
50. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, et al. IL-7 restores lymphocyte function in septic patients. J Immunol. 2012; 189: 5073–5081. doi: 10.4049/jimmunol.1202062 PMID: 23053510
51. Michaud A, Dardari RK, Charrier E, Cordeiro P, Herbiot S, Duval M. IL-7 enhances survival of human CD56bright NK cells. I Immunother. 2010; 33(4): 382–390. doi: 10.1097/CJI.0b013e3181cd872d PMID: 20386468
52. Cimbro R, Vassena L, Arthos J, Cicala C, Kehr JH, Park C, et al. IL7 induces expression and activation of integrin α4β7 promoting naïve T-cell homing to the intestinal mucosa. Blood. 2012; 120: 2610–2619. PMID: 22896005
53. Anderson A, Yang S-C, Huang M, Zhu L, Kar UK, Batra RK, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009; 182: 6951–6958. doi: 10.4049/jimmunol.0803340 PMID: 19454692
54. Schmitt N, Chene L, Bourolleau D, Nugeyre M, Guillemard E, Versmisse P, et al. Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4+ mature thyocytes correlates with their capacity to favor human immunodeficiency X4 virus replication. J Virol. 2003; 77: 5784–5793. PMID: 12719571
55. Srikkhajon K, Shynlova O, Preechapomprasert A, Chanrackul B, Lye S. A new role for Monocytes in modulating myometrial inflammation during human labor. Biol Reprod. 2014; 91(1): 10. doi: 10.1095/biolreprod.113.114975 PMID: 24829032
56. Rutella S, Zavaia F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol. 2005; 175 (11): 7085–7091. PMID: 16301609
57. Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N. Granulocyte-Colony Stimulating Factor related pathways tested on an endometrial ex-vivo model. PlosOne. 2014; 9 (10): e102286.
58. Lima PDA, Zhang J, Dunk C, Lye SJ, Croy BA. Leukocyte driven-decidual angiogenesis in early pregnancy. Cell Mol Immunol. 2014; 11: 522–537. doi: 10.1038/cmi.2014.63 PMID: 25066422